The company has made a concerted effort to expand its pharmaceutical activities in the last couple of years, setting up a dedicated pharma and biopharma unit last month and expanding its production capacity both through internal expansion and acquisition, e.g. the purchase of Bio Science Contract Production in 2001.
Robinson took up his new post yesterday, and joined Cambrex from Solutia UK where he was president of that company's pharmaceutical services division. Prior to Solutia, he was president of Lonza Biologics.
He will be responsible for managing the sales, marketing and commercial development of Cambrex pharma and biopharmaceutical products and services in Europe and Asia. In addition, he will oversee the management of the Cambrex facility in Cork, Ireland.
Gary Mossman, president and CEO of Cambrex's pharma and biopharma unit since being appointed to the post last month, said that Robinson would lead Cambrex's new initiatives in hazardous chemical handling, high containment, mammalian cell processing and polymer drug delivery.
Mossman joined Cambrex in March as the head of the company's pharmaceuticals unit, having previously been president of Dixie Chemicals, where he oversaw a concerted push into the pharmaceuticals sector.
Other recent appointments to the unit include Alexandra, who joined the pharma business unit in October as sales and business manager.